Amryt Pharma has today reported higher quarterly revenues as it marked its 11th consecutive quarter of positive EBITDA generation.
The company focuses on the development and commercialisation of treatments for orphan and rare diseases patients.
Amryt's revenues for the third quarter to the end of September rose by 8.2% to $61.1m, while it reported EBITDA of $12.5m.
Its Filsuvez drug for the treatment of EB in patients six months and older was approved in the UK during the quarter after its earlier approval in Europe over the summer. The drug has now been launched in Germany and it has seen good demand since its launch.
Its Mycapssa drug also saw a record quarter with quarterly and yearly revenue growth of 26.9% and 292.8% respectively.
It said it added an additional 31 new prescribers which brings the total new prescribers to 89, the vast majority of whom are community-based physicians.
Joe Wiley, CEO of Amryt Pharma, said today's strong operational and financial results reflect another excellent quarter for Amryt.
"These results demonstrate the robust growth we are experiencing and represent our eleventh consecutive quarter of positive EBITDA generation," he added.
"Given the strong underlying performance of our business year to date and notwithstanding the significant impact of the strengthening US dollar on our euro revenues, we are today reaffirming our full year 2022 revenue guidance of $260-$270m which represents growth of 17%-21% over 2021," he added.
